19.25亿美元！艾伯维引进CD3/BCMA/CD38三抗独苗

医药魔方Info2025-07-10

7月10日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGI Therapeutics达成独家许可协议，获得其主要资产ISB 2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据协议条款，IGI Therapeutics将获得7亿美元的预付款，并有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，以及基于净销售额的两位数分层特许权使用费...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2550625273?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-10 21:18","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2550625273","market":"us","top_or_hot":-1,"title":"19.25亿美元！艾伯维引进CD3/BCMA/CD38三抗独苗","media":"医药魔方Info","content":"<div>\n<p>7月10日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGI Therapeutics达成独家许可协议，获得其主要资产ISB 2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据协议条款，IGI Therapeutics将获得7亿美元的预付款，并有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，以及基于净销售额的两位数分层特许权使用费...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214346a6a1c554&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>19.25亿美元！艾伯维引进CD3/BCMA/CD38三抗独苗</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n19.25亿美元！艾伯维引进CD3/BCMA/CD38三抗独苗\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-10 21:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214346a6a1c554&s=b><strong>医药魔方Info</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>7月10日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGI Therapeutics达成独家许可协议，获得其主要资产ISB 2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据协议条款，IGI Therapeutics将获得7亿美元的预付款，并有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，以及基于净销售额的两位数分层特许权使用费...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214346a6a1c554&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z3581.USD","symbol_name":"Legg Mason ClearBridge - Value A Acc USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214346a6a1c554&s=b","article_id":"2550625273","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710214346a6a1c554&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2550625273","pubTimestamp":1752153485,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"ISB 2001是IGI Therapeutics基于其专有的BEAT蛋白平台开发一种同类首创的CD3/BCMA/CD38三特异性T细胞衔接器，通过同时靶向骨髓瘤细胞表达的BCMA和CD38来增强抗体在低靶标表达水平下的结合亲和力，并旨在通过增强靶向性来提高第一代双特异性抗体的安全性，具备治疗复发或难治性多发性骨髓瘤的潜力。目前，ISB 2001处于I期临床阶段，这也是目前唯一一款临床在研CD3/BCMA/CD38三抗。CD3和BCMA是血液瘤双抗/三抗药物开发的热门靶点。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4581":"高盛持仓","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4585":"ETF&股票定投概念","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","CR":"crane","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","BK4139":"生物科技","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","BK4550":"红杉资本持仓","ABBV":"艾伯维公司","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","PR":"Permian Resources Corp","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD"},"translate_title":"$1.925 billion! AbbVie introduces CD3/BCMA/CD38 tertiary antibody vaccine","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PR":1,"ABBV":0.9,"CR":1},"content_text":"7月10日，艾伯维宣布与Ichnos Glenmark Innovation的全资子公司IGI Therapeutics达成独家许可协议，获得其主要资产ISB 2001在北美、欧洲、日本和大中华区的独家开发、生产和商业化权益。根据协议条款，IGI Therapeutics将获得7亿美元的预付款，并有资格获得高达12.25亿美元的开发、监管和商业化里程碑付款，以及基于净销售额的两位数分层特许权使用费。ISB 2001是IGI Therapeutics基于其专有的BEAT®蛋白平台开发一种同类首创的CD3/BCMA/CD38三特异性T细胞衔接器，通过同时靶向骨髓瘤细胞表达的BCMA和CD38来增强抗体在低靶标表达水平下的结合亲和力，并旨在通过增强靶向性来提高第一代双特异性抗体的安全性，具备治疗复发或难治性多发性骨髓瘤的潜力。目前，ISB 2001处于I期临床阶段，这也是目前唯一一款临床在研CD3/BCMA/CD38三抗。ISB 2001已在I期研究中展现出治疗潜力。ASCO 2025大会上披露的数据显示，截至2025年1月13日，24例患者接受了8个剂量水平（5-1800μg/kg）的ISB 2001治疗，中位随访6个月时，所有剂量组的ORR达到75%，其中严格完全缓解（sCR）率为13%、完全缓解（CR）率为13%、非常好的部分缓解（VGPR）率为38%、部分缓解（PR）率为13%。从最低50μg/kg剂量组即观察到缓解（MRD阴性sCR），≥50μg/kg剂量组ORR达82%。中位缓解时间36天。CD3和BCMA是血液瘤双抗/三抗药物开发的热门靶点。据医药魔方数据库统计，全球共有7款同时靶向CD3和BCMA的三抗药物进入临床阶段，其中4款来自国内药企，包括GPRC5D/BCMA/CD3三抗IBI3003（信达生物）、MBS314（康源博创/天广实）、SCR-8572（先声药业）和QLS4131（齐鲁制药），其中SCR-8572已在今年1月被授权给艾伯维。推荐阅读：国产双抗/三抗霸榜ASCO 2025Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2550625273","isCrawlerRequest":true}